Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

2018 
10535Background: In preclinical pediatric cancer models, the HDAC inhibitor vorinostat showed significant activity only at higher concentrations compared with those achieved with currently recommen...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []